Regulation & law · 20/09/2002

U.S. Patent Application for Detecting Clostridium Botulinum Neurotoxin Serotypes Now Available for Licensing

The U.S. Patent and Trademark Office has made available the licensing of a U.S. patent application for a method to detect Clostridium botulinum neurotoxin serotypes A, B, E, and F in a sample, with foreign rights also available, as part of the government's efforts to promote innovation and technology transfer.